Focus on Advanced NSCLC: Expert Insights and Strategies for Refining Patient Care
  • Program Overview
    Focus on Advanced NSCLC: Expert Insights and Strategies for Refining Patient Care
    Explore key issues in the management of advanced NSCLC in this educational program designed to keep you abreast of rapidly evolving treatment practices. Gain expert insights on new developments as they emerge with the CME/CE-certified interactive modules, short expert commentaries, and the Interactive Decision Support Tool that will let you compare your treatment choices for specific patient scenarios in advanced NSCLC with those of 5 experts.
  • Featured content
    Download this checklist resource as a guide for important discussion points to have during your consultations with patients with advanced NSCLC and their caregivers.
    Date Posted: 1/25/2017
  • Featured content
    In this interactive, CME/CE-certified module, Alice Shaw, MD, PhD, provides her perspective on optimizing treatment strategies for advanced-stage ALK and ROS1 rearrangement–positive NSCLC.
  • Checkpoint inhibitor therapy is now approved for newly diagnosed metastatic NSCLC. Naiyer Rizvi, MD, discusses the latest clinical data from ESMO 2016 supporting this landmark change in advanced NSCLC management.
    Date Posted: 10/27/2016
  • Featured content
    In this interactive, CME/CE-certified module, Suresh S. Ramalingam, MD, provides expert perspective on optimizing treatment strategies for advanced-stage squamous NSCLC.
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

10 of 14 Shown
  • Combination Immunotherapy Plus Chemotherapy as First-line Therapy of Advanced NSCLC: Where Are We Now?

    H. Jack West MD - 4/11/2017 1 comment / Last Comment: 4/12/2017
    The combination of pembrolizumab plus carboplatin/pemetrexed for the first-line treatment of advanced NSCLC is currently under review by the FDA. In this commentary, I discuss my thoughts on the use of this regimen in patients with newly diagnosed advanced NSCLC.
  • Multidisciplinary Approaches to Maximize QoL in Patients With Advanced NSCLC

    Michele S. Barber MS, NP, AOCNP - 3/7/2017 1 comment / Last Comment: 3/9/2017
    Patients with advanced NSCLC are living longer. Michele S. Barber, MS, NP, AOCNP, discusses an active approach to addressing long-term cancer treatment adverse events and their impact on survivorship.
  • Advanced NSCLC: Expert Insight on the Selection of First-line and Second-line Therapy

    Use this Interactive Decision Support Tool to get treatment recommendations from David R. Gandara, MD; Martin J. Edelman, MD, FACP; Suresh S. Ramalingam, MD; Heather Wakelee, MD; and H. Jack West, MD, for your patients with advanced NSCLC.
    Date Posted: 2/27/2017
  • Managing Elderly Patients With Advanced NSCLC

    Jared Weiss MD - 1/30/2017 4 comments / Last Comment: 4/24/2017
    Should you use reduced intensity therapies for your elderly patients with advanced NSCLC? I discuss how to define “elderly” and my approach in caring for elderly patients with advanced NSCLC.
  • Consultation Checklist for Patients With Advanced NSCLC

    Download this checklist resource as a guide for important discussion points to have during your consultations with patients with advanced NSCLC and their caregivers.
    Date Posted: 1/25/2017
  • Clinical Focus cme-icon ce-icon

    Evidence-Based Treatment for ALK and ROS1 Rearrangement–Positive NSCLC

    In this interactive, CME/CE-certified module, Alice Shaw, MD, PhD, provides her perspective on optimizing treatment strategies for advanced-stage ALK and ROS1 rearrangement–positive NSCLC.
    Faculty: Alice Shaw MD, PhD
    Released: 12/28/2016
  • Evidence-Based Treatment for ALK and ROS1 Rearrangement–Positive NSCLC

    In this downloadable slideset, Alice T. Shaw, MD, PhD, highlights key studies for optimizing the management of patients with advanced-stage ALK and ROS1 rearrangement–positive NSCLC.
    Date Posted: 12/22/2016
  • Atezolizumab: A New Treatment Option for Progressive Metastatic NSCLC

    Melissa L. Johnson MD - 12/20/2016 5 comments / Last Comment: 2/6/2017
    There is now a third checkpoint inhibitor approved for metastatic NSCLC. Melissa L. Johnson, MD, discusses the latest clinical data from ESMO 2016 that led to the FDA approval of atezolizumab for advanced NSCLC that has progressed on previous platinum-based chemotherapy.
  • Clinical Dilemma: A Patient With a Diagnosis of Stage IV NSCLC-NOS Is Referred to You for a Second Opinion

    Leora Horn MD, MSc, FRCPC - 11/21/2016 2 comments / Last Comment: 11/28/2016
    In the age of targeted therapies and immune checkpoint inhibition, Leora Horn, MD, MSc, FRCPC, discusses the importance of avoiding diagnoses of lung cancer–not otherwise specified in the optimal treatment of patients with newly diagnosed, advanced NSCLC.
  • First-line Checkpoint Inhibitor Therapy in Metastatic NSCLC: A New Option for Our Patients

    Naiyer Rizvi MD - 10/27/2016 3 comments / Last Comment: 12/12/2016
    Checkpoint inhibitor therapy is now approved for newly diagnosed metastatic NSCLC. Naiyer Rizvi, MD, discusses the latest clinical data from ESMO 2016 supporting this landmark change in advanced NSCLC management.
10 of 14 Shown
Show 4 More
Loading...